Pembrolizumab - anti-PD-1 antibody

BIOLOGICAL2 trials

Sponsors

Linnaeus Therapeutics, Inc., Anwita Biosciences

Conditions

LymphomaNeoplasm MalignantNeoplasm, ExperimentalSolid Tumor, Adult

Phase 1

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Active, not recruitingNCT04130516

Linnaeus Therapeutics, Inc.Solid Tumor, Adult

Start: 2019-10-21End: 2026-08-15Target: 200Updated: 2026-07-13

Phase 1 First-in-human Study of JS014

Anwita BiosciencesLymphoma, Neoplasm, Experimental, Neoplasm Malignant +1

Start: 2022-02-28End: 2025-01-31Target: 60Updated: 2023-09-06

Related Papers

Ovariectomy-Induced Arterial Stiffening Differs From Vascular Aging and Is Reversed by GPER Activation

Hypertension2024-03-0614 citations

627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma

Regular and Young Investigator Award Abstracts2023-10-311 citations

The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.

Journal of Clinical Oncology2023-06-019 citations

G protein-coupled estrogen receptor in GtoPdb v.2023.1

IUPHAR/BPS Guide to Pharmacology CITE2023-04-26

759 Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors

Regular and Young Investigator Award Abstracts2022-11-013 citations

Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.

Journal of Clinical Oncology2022-06-0117 citations

G protein-coupled estrogen receptor in GtoPdb v.2021.3

IUPHAR/BPS Guide to Pharmacology CITE2021-09-02

Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

Journal of Clinical Oncology2021-05-2017 citations